Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces positive results from EVIDENCES IV Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD and NASH

Posted On: 2019-10-03 09:30:26

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that Saroglitazar Magnesium has achieved the primary end-points in the EVIDENCES IV trial in patients with NAFLD and NASH.

The EVIDENCES IV NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic Steatohepatitis (NASH) across 20 clinical sites in the United States of America. Patients were randomly assigned in a ratio of 1:1:1:l to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks.

Prof. Naga P. Chalasani, MD, Associate Dean for Clinical Research and Director, Division of Gastroenterology & Hepatology, Indiana University School of Medicine, USA, an authority in the fields of NAFLD and drug induced liver injury (DILI), was the lead Principal Investigator of the EVIDENCES IV trial. Prof. Chalasani stated "Saroglitazar 4 mg significantly improved liver biochemistries, hepatic steatosis, dyslipidemia, and insulin resistance, with no weight gain or fluid retention. These results are quite encouraging as there is a significant unmet need for patients with NAFLD and NASH for a drug that improves not just the liver disease, but important comorbidities such as insulin resistance and dyslipidemia."

Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, "We are happy with the positive results that Saroglitazar Magnesium has shown in the EVIDENCES IV trial. We look forward to presenting the detailed data in upcoming scientific conferences and publishing the study findings in peer-reviewed scientific journals."

The primary endpoint ofthe study was percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group. There was a statistically significant reduction in mean ALT from baseline to week 16 observed with all doses of Saroglitazar as compared to placebo.

A statistically significant reduction in hepatic fat content from baseline was observed in patients treated with Saroglitazar Magnesium as compared to placebo following 16 weeks of treatment as measured by MRI-PDFF. The secondary endpoints of the trial also included measurements of other Liver enzymes, Insulin resistance, Liver fibrosis, BMI, Waist circumference, MRI-derived measures oftotal liver fat index, Lipid and lipoprotein levels, and pharmacokinetic parameters.

This study is one of several EVIDENCES trials conducted to assess the effect of Saroglitazar Magnesium in various populations with NAFLD, including patients with NASH.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.233.05 as compared to the previous close of Rs. 233.45. The total number of shares traded during the day was 80419 in over 1313 trades.

The stock hit an intraday high of Rs. 237 and intraday low of 228. The net turnover during the day was Rs. 18734405.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Ambuja Cements Ltd Q4 CY2019 consolidated PAT lower at Rs. 591.54 crore

ICRA revises long term rating of Indiabulls Housing Finance Limited

GMR Infrastructure Limited announces Strategic Partnership with Groupe ADP for Airports Business

Muthoot Finance Ltd announces pricing of USD 550 million 4.40% notes

UFO Moviez India Ltd board to consider interim dividend on Feb 27, 2020

Dr. Reddy's Laboratories Ltd receives EIR for Duvvada Formulations Plant

Dhanlaxmi Bank Ltd receives RBI nod for appointment of MD & CEO

Sharda Cropchem Ltd Board to consider Second Interim Dividend for FY20

Ambuja Cements Ltd Board recommends Dividend of Rs. 1.50 for CY2019

Plastiblends India Ltd board to consider interim dividend on Feb 25, 2020

Cyient Organizes Blood Donation Drive at its Hyderabad Campus

TCS Named as One of the Fortune Best Big Companies to Work For™ in 2020

India Infoline Finance Ltd raises $400 million

Ambuja Cements Limited appoints Mr. Neeraj Akhoury as new MD and CEO

Garware Technical Fibres Ltd to dispose business undertaking in USA

AstraZeneca Pharma India Ltd launches FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)

DCW Limited is the biggest beneficiary of the recently announced anti-dumping duty on imported C-PVC

Jubilant FoodWorks Ltd Board to consider interim dividend on Feb 27, 2020

Jubilant Life Sciences Ltd board to consider interim dividend for FY2020

JK Paper Ltd board to consider interim dividend on Feb 27, 2020

Shri N Baijendra Kumar, CMD, NMDC wins Business Leadership Award

Cyril Amarchand Mangaldas Advises Avenue Supermarts Limited on its INR 4098 Cr. QIP

PVR Ltd board to declare interim dividend on Feb 28, 2020

ICRA assigns ratings to KPIT Technologies Ltd

A.M. Best Affirms A-(Excellent) Rating of The New India Assurance Company Limited

Cipla Ltd board to consider interim dividend for FY2020

SBI Cards IPO to open for subscription on March 2, 2020

Axis Bank to explore long-term strategic partnership with Max Life

Genus Power wins 'Innovative Initiative in the Power Sector', 2020 award for its Smart Metering Pilot project in UAE

JK Cement Ltd board to consider interim dividend on Feb 28, 2020

Shoppers Stop Ltd closes stores at Orion East Mall, Bengaluru and Grant Mall, Chennai

KRBL Ltd board to consider interim dividend for FY2020

Future Lifestyle Fashions Ltd board approves issue of securities to IFC

Trident Ltd board declares interim dividend of Rs. 0.18

Century Plyboards India Ltd forms new subsidiary company

Valiant Organics Ltd board to consider 2nd interim dividend on Feb 28, 2020

Sonata Software Ltd board to consider interim dividend on Feb 26, 2020

JB Chemicals & Pharmaceuticals Ltd board declares interim dividend of Rs. 10

Anuh Pharma Ltd receives CEP for Ambroxol Hydrochloride for EU market

TCS Positioned as a Leader in Application Transformation Services by Everest Group

CARE Ratings Limited updates on ratings of Pitti Engineering Ltd

HGS Recognized on IAOP's 'The 2020 Global Outsourcing 100®' List

Shreyas Shipping & Logistics Ltd announces sale of Vessel 'SSL Kutch'

Redington India Ltd board approves 2nd interim dividend of Rs. 2.80

Cholamandalam Investment and Finance Company Ltd board to consider interim dividend for FY20

Tarini International Ltd updates on SEBI AO Order

Sunteck Realty Ltd has sold 1800 apartments at Sunteck MaxXWorld

Thomas Cook India Ltd board to consider buy back on Feb 26, 2020

Delhi International Airport Ltd offers $150 mn senior secured notes

IndiGo to enable faster ground operations and reduce aircraft turn-around time with WheelTug Systems







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019